Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent

References

• Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin. Infect. Dis.29, 239–244 (1999).
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis.39, 309–317 (2004).
   PubMed Web of Science ®Google Scholar
• Wenzel RP. Attributable mortality: the promise of better antimicrobial therapy. J. Infect. Dis.178, 917–919 (1998).
   PubMedGoogle Scholar
• Farver DK, Hedge DD, Lee SC. Ramoplanin: a lipoglycodepsipetide antibiotic. Ann. Pharmacother.39, 863–868 (2005).
   PubMed Web of Science ®Google Scholar
• Walker S, Chen L, Hu Y, Rew Y, Shin D, Boger DL. Chemistry and biology of ramoplanin: a lipo-glycodepsipeptide with potent antibiotic activity. Chem. Rev.105, 449–475 (2005).
   PubMed Web of Science ®Google Scholar
• Montecalvo MA. Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients. J. Antimicrob. Chemother.51(S3), 31–35 (2003).
   Google Scholar
• Cavalleri B, Pagani H, Volpe G, Selva E, Parenti F. A-16686, a new antibiotic from actinoplanes. I. Fermentation, isolation and preliminary physico-chemical characteristics. J. Antibiotic.37, 309–317 (1984).
   PubMed Web of Science ®Google Scholar
• Pittet D, Davis CS, Li N, Wenzel RP. Identifying the hospitalized patient at risk for nosocomial bloodstream infection: a population-based study. Proc. Assoc. Am. Physicians109, 58–67 (1997).
   PubMedGoogle Scholar
• Davey P, Brown E, Fenelon L et al. Systematic review of antimicrobial drug prescribing in hospitals. Emerg. Infect. Dis.12, 211–216 (2006).
   PubMed Web of Science ®Google Scholar
• Kreman T, Hu J, Pottinger J, Herwaldt LA. Survey of long-term facilities in Iowa policies and practices regarding patients with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci. Infect. Control Hosp. Epidemiol.26, 811–815 (2005).
   PubMedGoogle Scholar
• Mody L, Kauffman CA, McNeil SA, Galecki AT, Bradley SF. Mupirocin-based decolonization of Staphylococcus aureus carriers in residents of 2 long-term care facilities: a randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis.37, 1467–1474 (2003).
   PubMed Web of Science ®Google Scholar
• Simor AE, Bradley SF, Strausbaugh LJ, Crossley K, Nicolle LE; SHEA Long-Term-Care Committee. Clostridium difficile in long term-care facilities for the elderly. Infect. Control Hosp. Epidemiol.23, 696–703 (2003).
   Google Scholar
• Kluytmans-Vandenbergh MF, Kluytmans JA. Community-acquired methicillin-resistant Staphylococcus aureus: current perspectives. Clin. Microbiol. Infect.12(Suppl. 1), 9–15 (2006).
   PubMed Web of Science ®Google Scholar
• Rybak MJ, LaPlante KL. Community-associated methicillin-resistant Staphylococcus aureus: a review. Pharmacotherapy25, 74–85 (2005).
   PubMed Web of Science ®Google Scholar
• Genestier AL, Michallet MC, Prevost G et al. Staphylococcus aureus Panton-Valentine leukocidin directly targets mitochondria and induces Bax-dependent apoptosis of human neutrophils. J. Clin. Invest.115, 3117–3127 (2005).
   PubMed Web of Science ®Google Scholar
• Jiang W, Wanner J, Lee RJ, Bounaud PY, Boger DL. Total synthesis of the ramoplanin A2 and ramoplanose aglycon. J. Am. Chem. Soc.125, 1877–1887 (2003).
   PubMedGoogle Scholar
• Pallanza R, Berti M, Scotti R, Randisi E, Arioli V. A-16686, a new antibiotic from actinoplanes. II. Biological properties. J. Antibiotic.37, 318–324 (1984).
   PubMed Web of Science ®Google Scholar
• Ciabatti R, Kettenring JK, Winters G, Tuan G, Zerilli L, Cavalleri B. Ramoplanin (A-16686), a new glycolipodepsipeptide antibiotic. III. Structure elucidation. J. Antibiotic.42, 254–67 (1989).
   PubMedGoogle Scholar
• Somner EA, Reynolds PE. Inhibition of peptidoglycan biosynthesis by ramoplanin. Antimicrob. Agents Chemother.34, 413–419 (1990).
   PubMed Web of Science ®Google Scholar
• Reynolds PE, Somner EA. Comparison of the target sites and mechanisms of action of glycopeptide and lipoglycodepsipeptide antibiotics. Drugs Exptl Clin. Res.16, 385–390 (1990).
   PubMedGoogle Scholar
• Lo MC, Men H, Branstrom A et al. A new mechanism of action proposed for ramoplanin. J. Am. Chem. Soc.122, 3540–3541 (2000).
   Google Scholar
• Hu Y, Helm JS, Chen L, Ye XY, Walker S. Ramoplanin inhibits bacterial transglycosylases by binding as a dimer to Lipid II. J. Am. Chem. Soc.125, 8736–8737 (2003).
   PubMedGoogle Scholar
• Ha S, Walker D, Shi Y, Walker S. The 1.9 A crystal structure of Escherichia coli MurG, membrane-associated glycosyltransferase involved in peptidoglycan biosynthesis. Protein Sci.9, 1045–1052 (2000).
   PubMed Web of Science ®Google Scholar
• Chen L, Yuan Y, Helm JS et al. Dissecting ramoplanin: mechanistic analysis of synthetic ramoplanin analogues as a guide to the design of improved antibiotics. J. Am. Chem. Soc.126, 7462–7463 (2004).
   PubMedGoogle Scholar
• Shin D, Rew Y, Boger DL. Total synthesis and structure of the ramoplanin A1 and A3 aglycons: two minor components of the ramoplanin complex. Proc. Natl Acad. Sci. USA101, 11977–11979 (2004).
   PubMedGoogle Scholar
• Ling LL, Fan J, Schumacher T, Borsari B, Davey M, Puyang X. Over-expression of murG in S. aureus does not alter the ramoplanin MIC (Abstracts). Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. IL, USA, 14–17 September (2003).
   Google Scholar
• Goossens H, Jabes D, Rossi R et al. European survey of Vancomycin-resistant enterococci in at-risk hospital wards and in vitro susceptibility testing of ramoplanin against these isolates. J. Antimicrob. Chemother.51(Suppl. 3) 5–12 (2003).
   PubMedGoogle Scholar
• Mobarakai N , Quale JM, Landman D. Bactericidal activities of peptide antibiotics against multi drug-resistant Entercoccus faecium. Antimicrob. Agents Chemother.38, 385–387 (1994).
   PubMed Web of Science ®Google Scholar
• Pelaez T, Alcala A, Alonso R et al. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Antimicrob. Agents Chemother.49, 1157–1159 (2005).
   PubMed Web of Science ®Google Scholar
• Citron DM, Merriam CV, Tyrrell KL et al. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin and four other antimicrobials against international aerobic bacteria. Antimicrob. Agents Chemother.47, 2334–2338 (2003).
   PubMed Web of Science ®Google Scholar
• de Lalla F, Romeo B, Nicolin R, Pallizzer G, Merati R, Riva E. Oral ramoplanin (R) single-dose administration in pseudomembranous colitis (PMC). Can. J. Infect. Dis.6(Suppl. 5), 452C (1995).
   Google Scholar
• Romeo B, Kaschub M, Cavenaghi L et al. Repeated doses of ramoplanin orally administered to healthy and male volunteers: tolerability, lack of absorption and effect on the stool microflora (Abstracts). Presented at: 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. DC, USA (1993).
   Google Scholar
• Wong MT, Kauffman CA, Standiford HC et al. Effective suppression of vancomycin-resistant enterococci species in asymptomatic gastrointestinal carriers by a novel glycolipodespsipeptide, ramoplanin. Clin. Infect. Dis.33, 1476–1482 (2001).
   PubMed Web of Science ®Google Scholar
• Pullman J, Prieto J, Leach TS. Ramoplanin vs. vancomycin in the treatment of Clostridium difficile diarrhea: a Phase II study (Abstracts). Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. DC, USA, 30 October–2 November (2004).
   Google Scholar
• Bricker E, Garg R, Nelson R et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst. Rev.25(1), CD004610 (2005).
   Google Scholar
• Loo VG, Poirer L, Miller M et al. A predominately clonal multi-institutional outbreak of Clostridium difficile associated diarrhea with high morbidity and mortality. N. Engl. J. Med.353, 2442–2449 (2005).
   PubMed Web of Science ®Google Scholar